Bli medlem
Bli medlem

Du är här

2019-03-08

Nanologica: Nanologica to attend BIO-Europe Spring 2019 in Vienna for partnering discussions

Nanologica will be attending BIO-Europe Spring 2019 in Vienna, Mar. 25
- 27 to meet with potential pharmaceutical partners regarding
co-development and licensing of NIC-001, Nanologica's drug candidate
for treating gastroparesis, as well as seeking partnership for
further drug delivery applications using NLAB Silica™.

Nanologica strives to be the world leader in nanoporous silica
particles in its two business areas: Drug Delivery and
Chromatography. Nanologica has developed a drug delivery platform
based on its nanoporous silica particles, NLAB Silica™, for improved
delivery and absorption of active pharmaceutical ingredients.

By loading the API in NLAB Silica™ particles, Nanologica can overcome
several of the challenges that prevent or limit effective treatment
of many serious diseases. Some of the benefits of using NLAB Silica™
includes stabilization and protection of the API, controlled release
and increased solubility of the API.

Nanologica is currently involved in several clinical trials, with its
own asset, NIC-001, which is a drug candidate in phase II for the
treatment of gastroparesis, aa well as in collaboration projects with
large and mid-size pharma. On January 30, 2019, Nanologica and
AstraZeneca entered into an agreement for the evaluation of
Nanologica's technology applied to AstraZeneca materials. On May 16,
2018 Nanologica licensed parts of its technology platform to Vicore
Pharma AB for use in several of their upcoming clinical trials.

Nanologica is interested in partnering with pharma companies within
the gastrointestinal area and is also seeking partnership for further
drug delivery applications using NLAB Silica™.

To schedule a meeting, please do so via BIO-Europe's online partnering
platform at: www.partneringone.com
(http://www.partneringone.com/app/log_on_select.php), or contact:

Kia Bengtsson, Director Clinical Development, Nanologica AB

phone: +46 70 144 36 30 or e-mail kia.bengtsson@nanologica.com

For technical information on Nanologica's drug delivery platform,
please contact:

Prof. Adam Feiler, CTO Nanologica AB

phone: +46 72 353 66 30 or e-mail adam.feiler@nanologica.com

For further information, please contact:

Andreas Bhagwani, CEO Nanologica AB
phone: +46 70 316 17 02 or e-mail: andreas.bhagwani@nanologica.com

About Nanologica
Nanologica AB (publ) develops nanoporous silica for applications in
life science. The company focuses on two business areas: drug
delivery and chromatography, a technology used for the separation and
purification of products on the market and in development.
Nanologica's core competency is to apply its unique know-how in the
field of material science for developing nanoporous silica particles
with unique characteristics. The company's stock is traded on
Spotlight Stock Market (ticker NICA). For more information, please
visit www.nanologica.com.

Tel: +46 70 316 17 02 eller e-post: andreas.bhagwani@nanologica.com

-----------------------------------------------------------
https://news.cision.com/se/nanologica/r/nanologica-to-attend-bio-europe-...
https://mb.cision.com/Main/13073/2759430/1004385.pdf

Författare Aktietorget

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.